Product Description

Extended-Protocol Triple-Agonist Vial (30mg)

Retatrutide (30mg) is supplied in Australia by Daza Enhanced with fast domestic shipping to all states and territories.

The 30mg vial supports extended Retatrutide research protocols. At a standard 2mg weekly application, 30mg covers approximately 15 weeks of uninterrupted research from a single batch-verified vial.

Phase 2 clinical trials reported a mean body weight reduction of up to 24% over 48 weeks — outperforming semaglutide and tirzepatide in head-to-head comparisons. Retatrutide’s triple-receptor activity targets three pathways simultaneously: appetite regulation via GLP-1, fat metabolism and insulin sensitivity via GIP, and increased energy expenditure via glucagon receptor activation.

Key Research Areas

• Fat Loss Research — including visceral adiposity, across extended protocols
• Appetite Regulation — sustained food intake reduction over multi-month research windows
• Cardiometabolic Markers — blood pressure, LDL cholesterol, waist circumference
• Energy Expenditure — via glucagon receptor activation
• Comparative Research — outperforms semaglutide and tirzepatide in head-to-head data

Supplied as lyophilized powder at ≥99% purity, verified by HPLC and mass spectrometry. 30mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.